Mark T. Iwicki Sells 5,779 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $44,093.77. Following the sale, the chief executive officer now owns 280,076 shares in the company, valued at $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

KALA BIO Stock Performance

NASDAQ:KALA opened at $6.82 on Thursday. The firm has a market capitalization of $31.44 million, a PE ratio of -0.55 and a beta of -2.11. The stock’s fifty day moving average is $6.71 and its 200 day moving average is $6.32. KALA BIO, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $9.25. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. On average, sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises approximately 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.